Novavax Inc.

Novavax, a leading biotech, develops recombinant‑protein vaccines using its Matrix‑M adjuvant, with an approved COVID‑19 shot (Nuvaxovid/Covovax) and a promising malaria candidate, positioning it as a diversified vaccine platform player.

Headquarters: United States (USA)

Website: Visit Site 🔗
Type: Corporation

Company Profile

Sector: Professional Services
Industry: Biotechnology Research

Employees: 952
HQ: Gaithersburg

Unlock the full potential.

Get access to Relative P/E Ratio Valuation Histogram.

Upgrade

Traded Instruments

+ Add Instrument 1

Symbol	Name	Type	Exchange	Currency	ISIN	Status	Actions
NVAX	Novavax Inc. Cap: 1.2B \| P/E: 3.6	EQUITY	NMS	USD	US6700024010	Active	📈